This paragraph requires the student to return all trade secrets to the revealing party when the notion of research or study ends. There is nothing to add here. Stanford`s policy allows researchers to sign NDAs in their own property. IPs and other members of the study team are not eligible to sign on behalf of Stanford University. Clinical Trial Contract Officers (CT CO) of the Research Management Group (RMG) have designated the signature authority for the negotiation and signing of the NDAs on behalf of Stanford University. In order to ensure that the information, knowledge or results of the search disclosed to another party remain confidential and are not misused, a confidentiality agreement (CDA) or confidentiality agreement (NDA) should be established between the supplier and the recipient of this information. The sponsor or cro often provides its own NOA model; Stanford, however, prefers to use the Accelerated Confidential Disclosure Agreement (ACDA), which was developed by a team of academic medical centers, universities (including Stanford), industry sponsors and CROs to reduce NDAs trading time. In addition, Stanford uses pre-negotiated NDAs masters with a few frequent clinical trial sponsors to reduce trading time, protect Stanford`s interests and support Stanford`s academic policy. These offices have been given exclusive authority to negotiate terms that are consistent with university and state policies, and they also have the exclusive power to sign NDAs on behalf of the university.

The researcher cannot sign on behalf of the university. However, the researcher is invited, along with other project participants, to sign a confirmation in order to comply with the terms of the agreement. A Confidential Disclosure Agreement [CDA), also known as the Confidentiality Agreement (NDA), is a legal agreement between at least two parties, which describes information that the parties wish to share for evaluation purposes, but which wish to restrict wider use and dissemination. The parties undertake not to disclose the non-public information covered by the agreement. CDAs are often performed when two parties are considering a relationship/cooperation and must understand the processes, methods or technologies of the other party only for the purpose of assessing the potential of a future relationship. For industry-sponsored clinical trials, the sponsored or contracted research organization (CRO) generally requires Stanford or IP to enter into a non-discloser agreement (NDA) before sharing the study protocol and other proprietary documents. The NDA protects the confidentiality of the details of the procedure. An NOA can also be referred to as a Confidential Disclosure Agreement (CDA) or confidentiality agreement. If PI receives information from the sponsor or CRO that does not require distribution to others, the IP may sign the agreement on its own behalf. If PI signs as an individual, he will be personally responsible for the management of protected confidential information and should not disclose or disclose the information to individuals who have not signed a similar NOA with the sponsor or the CRO.